Insider Selling: Alphatec (NASDAQ:ATEC) EVP Sells 60,425 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 60,425 shares of Alphatec stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $13.79, for a total transaction of $833,260.75. Following the transaction, the executive vice president directly owned 349,500 shares in the company, valued at $4,819,605. This trade represents a 14.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

David Sponsel also recently made the following trade(s):

• On Wednesday, December 10th, David Sponsel sold 21,106 shares of Alphatec stock. The stock was sold at an average price of $20.79, for a total transaction of $438,793.74.
• On Monday, December 8th, David Sponsel sold 988 shares of Alphatec stock. The shares were sold at an average price of $21.45, for a total transaction of $21,192.60.

Alphatec Trading Up 2.4%

Alphatec stock traded up $0.32 during mid-day trading on Friday, hitting $13.82. The company’s stock had a trading volume of 2,253,779 shares, compared to its average volume of 3,827,759. The stock’s fifty day moving average is $19.03 and its two-hundred day moving average is $16.98. The company has a current ratio of 1.99, a quick ratio of 1.24 and a debt-to-equity ratio of 43.02. The firm has a market capitalization of $2.05 billion, a PE ratio of -13.29 and a beta of 1.01. Alphatec Holdings, Inc. has a 1 year low of $8.81 and a 1 year high of $23.29.

Analyst Ratings Changes

ATEC has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Alphatec in a research note on Monday, January 12th. Loop Capital set a $25.00 price objective on shares of Alphatec in a research report on Wednesday, December 10th. TD Cowen reiterated a “buy” rating on shares of Alphatec in a report on Tuesday, January 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Alphatec in a research note on Monday, December 29th. Finally, JPMorgan Chase & Co. started coverage on Alphatec in a research report on Friday, October 24th. They set an “overweight” rating and a $19.00 price target for the company. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Alphatec has a consensus rating of “Moderate Buy” and a consensus target price of $22.82.

Institutional Trading of Alphatec

Hedge funds have recently modified their holdings of the stock. Aster Capital Management DIFC Ltd acquired a new position in Alphatec during the 3rd quarter worth $34,000. Osterweis Capital Management Inc. acquired a new stake in Alphatec in the 2nd quarter valued at about $37,000. Nisa Investment Advisors LLC boosted its stake in shares of Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after buying an additional 1,045 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Alphatec during the third quarter worth about $73,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Alphatec during the third quarter worth approximately $74,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.